Browsing by Author Osorio, Santiago

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)
2017A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
2018Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
2015-12-03Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method
Garcia-Gutierrez, Valentin; Gomez Casares, Maria Teresa; Velasco Antonio, Jimenez; Juan Manuel, Alonso; Osorio, Santiago; Carlos Hernandez-Boluda, Juan; Manuel Puerta, Jose; Collado, Rosa; Jose Ramirez, Maria; Ibaaez, Fatima; Martin Mateos, Maria Luisa; Rodriguez Gambarte, Juan Diego; Martinez Laperche, Carolina; Redondo, Sara; Gomez, Montse; Suarez Fiallo, D. V.; Rodriguez Fernandez, Alicia; Ruiz, Concepcion; Luis Steegmann, Juan; [Garcia-Gutierrez, Valentin] Hosp Ramon & Cajal, Dept Hematol, E-28034 Madrid, Spain; [Gomez Casares, Maria Teresa] Hosp Univ Doctor Negrin, Dept Hematol, Las Palmas De Gran Canai, Spain; [Velasco Antonio, Jimenez;Ruiz, Concepcion] Hosp Reg Univ Malaga, Serv Hematol, Malaga, Spain; [Juan Manuel, Alonso] Hosp Infanta Sofia, Lab Cent Br Salud, Madrid, Spain; [Osorio, Santiago;Martinez Laperche, Carolina;Redondo, Sara] Hosp Univ Gregorio Maranon, Serv Hematol, Madrid, Spain; [Carlos Hernandez-Boluda, Juan;Gomez, Montse] Hosp Clin, Dept Hematol, Valencia, Spain; [Manuel Puerta, Jose] Hosp Univ Virgen de las Nieves, Unidad Gest Clin Hematol & Hemoterapia, Granada, Spain; [Collado, Rosa] Consorcio Hosp Gen Univ, Serv Hematol, Genet Lab, Valencia, Spain; [Jose Ramirez, Maria] Hosp Jerez de la Frontera, Dept Hematol, Jerez De La Frontera Cad, Spain; [Ibaaez, Fatima;Martin Mateos, Maria Luisa] Hosp San Pedro Alcantara, Serv Extremeno Salud, Serv Hematol, Caceres, Spain; [Rodriguez Gambarte, Juan Diego] Hosp Univ Ramon y Cajal, Dept Hematol, Madrid, Spain; [Suarez Fiallo, D. V.] Hosp Univ Doctor Negrin, Dept Hematol, Las Palmas Gran Canaria, Spain; [Rodriguez Fernandez, Alicia] Hosp Virgen de la Macarena, Serv Hematol, Seville, Spain; [Luis Steegmann, Juan] Hosp Univ Princesa, Inst Invest Sanitaria, Madrid, Spain
2017PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.
2015-07Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.